Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (November 2016)

17 slides from Sorrento Therapeutics's investor presentation, November 2016

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation November 2016

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking statements” as defined in th

  3. Slide 3: Sorrento Therapeutics Overview

    Slide 3: Sorrento Therapeutics Overview

    Sorrento Therapeutics Overview › Antibody-centric, clinical stage biopharmaceutical company founded in 2006 Partners Subs/JVs › Goal: to deliver clinically meaningful therapies to patients and leverage on proprietary targeted and cellular therapy platforms › Focus: immuno-oncology, hematology, auto-

  4. Slide 4: Core Technologies and Programs Under Development

    Slide 4: Core Technologies and Programs Under Development

    Core Technologies and Programs Under Development CAR-based › Autologous and allogeneic CAR-T and CAR.NK therapies Immunotherapies › Targets include CD38, CD123, CEA, and PSMA Intracellular Delivery of › Proprietary platform enables modulation of intracellular targets with antibody therapeutics › Gre

  5. Slide 5: Corporate Structure

    Slide 5: Corporate Structure

    Corporate Structure Pain Management: Scintilla Scilex Sorrento Therapeutics © 2016 5

  6. Slide 6: Antibody Therapeutics: G-MAB Library

    Slide 6: Antibody Therapeutics: G-MAB Library

    Antibody Therapeutics: G-MAB Library Difficult Targets High Value Oncology Targets G Protein-Coupled Receptors Small Peptides & Tumor Neo-epitopes PD1, PD-L1, CD123, TIM3, CD47 (GPCRs) F L S Y G N A G AIP-2 One of the Largest Fully Human Highly Successful Screening Hit Rate Antibody Libraries 100+ c

  7. Slide 7: Antibody Therapeutics: Pipeline

    Slide 7: Antibody Therapeutics: Pipeline

    Antibody Therapeutics: Pipeline Lead Candidates in Development 2016 H2 H1 2017 H2 H1 2018 H2 Antibodies › STI-A1014 (PD-L1 mAb) STI-A1014 (Lee's Pharma) IND Filing in China/HK Initiation of Clinical Trials o CN Clinical trial initiation expected in 1H17 STI-A1015 (ImmuneOncia) IND Filing / Trial Ini

  8. Slide 8: Antibody Therapeutics: Anti-PD-1 Transaction with Servier

    Slide 8: Antibody Therapeutics: Anti-PD-1 Transaction with Servier

    Antibody Therapeutics: Anti-PD-1 Transaction with Servier › On July 6, 2016 Sorrento announced a license and collaboration agreement with Laboratoires Servier for the development, manufacture and commercialization of products using Sorrento’s fully human immuno-oncology anti-PD-1 mAb STI-A1110 o STI

  9. Slide 9: Sorrento Biologics: Biosimilars and Biobetters

    Slide 9: Sorrento Biologics: Biosimilars and Biobetters

    Sorrento Biologics: Biosimilars and Biobetters Pipeline Overview › Exclusive licensing agreement with Mabtech Limited to develop and commercialize biosimilar antibodies › 4 antibodies to-date, targeting ~$9B global market: Sorrento Global Sales Generic Target Brand Antibody (2015 WW) STI-001 Cetuxim

  10. Slide 10: LA Cell: iTAb (Intracellular Targeting Antibody) Platform

    Slide 10: LA Cell: iTAb (Intracellular Targeting Antibody) Platform

    LA Cell: iTAb (Intracellular Targeting Antibody) Platform Current mAb/protein drugs target extracellular proteins, either New Class of Drugs for Unmet secreted or membrane bound Medical Needs 2015 sales < 10% potential $169 billion druggable space LA Cell’s proprietary iTAb platform enables the abil

  11. Slide 11: LA Cell: "Undruggable" Intracellular Targets

    Slide 11: LA Cell: "Undruggable" Intracellular Targets

    LA Cell: “Undruggable” Intracellular Targets All Targets Druggable by Sorrento / LA Cell iTAb technology STAT3 MYC Mutant KRAS FOXP3 T-bet TAU Autoimmune Alzheimer’s Solid Tumors Solid Tumors Solid Tumors Solid Tumors Diseases Disease Autoimmune Hematological Parkinson’s GVHD Diseases Malignancies D

  12. Slide 12: LA Cell: Building the Leading Intracellular Targeting Antibody (iTAb) Company

    Slide 12: LA Cell: Building the Leading Intracellular Targeting Antibody (iTAb) Company

    LA Cell: Building the Leading Intracellular Targeting Antibody (iTAb) Company Program Stage Activities In-Vivo Efficacy Studies STAT3 Lead Optimization Developability Assessment MYC Lead Discovery Functionality Evaluation FOXP3 Lead Discovery Antibody Modification KRAS Lead Discovery Antibody Modifi

  13. Slide 13: Concortis Biotherapeutics: Antibody-Drug Conjugates (ADCs)

    Slide 13: Concortis Biotherapeutics: Antibody-Drug Conjugates (ADCs)

    Concortis Biotherapeutics: Antibody-Drug Conjugates (ADCs) Next-Generation Antibody-Drug Conjugates › Cytotoxic drugs conjugated to antibodies via chemical linkers › Site-specific conjugation methods to provide homogenous products o K-Lock™ and C-Lock™ › Proprietary toxins: tubulin-binding, DNA alky

  14. Slide 14: Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs

    Slide 14: Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs

    Scintilla & Scilex Pharmaceuticals: Late-Stage Pain Management Programs RTX SP-102 ZTlido™ (resiniferatoxin) (lidocaine patch 1.8%) • Non-opiate epidural steroid • Non-opioid-based ultrapotent injectable • Anhydrous, single-layer lidocaine Asset Overview TRPV1 agonist neurotoxin injectable • ~10M ep

  15. Slide 15: Global Partners: Immuno-Oncology, Cellular Therapy, ADC

    Slide 15: Global Partners: Immuno-Oncology, Cellular Therapy, ADC

    Global Partners: Immuno-Oncology, Cellular Therapy, ADC Partner Asset Type Partner Background Partnership Details • License and collaboration agreement for the development, manufacture and • Servier is the largest non-listed pharmaceutical Laboratoires Servier Immuno-Oncology company in France comme

  16. Slide 16: 2016 Strategic Accomplishments

    Slide 16: 2016 Strategic Accomplishments

    2016 Strategic Accomplishments • Servier PD-1 mAb license validates core G-MAB technology with potential development and Core Technology Validation commercial milestones totaling over $1 billion • Pain management franchise built out and moving forward with internal investments and acquisitions (SCIL

  17. Slide 17: Contact Us

    Slide 17: Contact Us

    Contact Us (858) 210-3700 9380 Judicial Drive, San Diego, CA 92121 [email protected] Sorrento Therapeutics © 2016 17

Source: company website

More decks from Sorrento Therapeutics, Inc.

All 41 Sorrento Therapeutics decks